Home > Directory > Physicians / Faculty > Jas C. Lang, PhD > Dr. Lang's OSU:pro Profile

Dr. Lang's OSU:pro Profile

Staff photo

Tzagournis Medical Research Facility
Columbus, OH 43210

Phone: (614) 292-6026

Email: lang.8@osu.edu

Current OSU Appointment

Associate Professor, Otolaryngology

Editorial Activities

Reviewer

NIH/NCI-F T32/K99/R00. (Study Section)

Honors

2004	Brown Memorial Lectureship. Columbus Otolaryngological Society.

Peer Reviewed Journal Articles

Lonsdale DM, Brown SM, Lang JC, Subak-Sharpe JH, Koprowski H and Warren KG. 1980. Variations in herpes simplex virus isloated from human ganglia and a study of clonal variation in HSV-1. Ann. N.Y. Acad. Sci. Vol. 354: 291-308.

Marsden HS, Lang JC, Davison AJ, Hope RG, and McDonald DM. 1982. Genomic Location and lack of phosphorylation of the HSV immediate-early polypeptide IE 12. Journal of Gen. Virol. Vol. 62: 17-27.

Campo MS, Spandidos DA. 1983. Transcriptional control signals in the genomeof papillomaviruses type 1. Nature. Vol. 303: 77-80.

Lang JC; Wilkie NM; Spandidos DA. 1983. Characterization of eukaryotic transcriptional control signals by assay of herpes simplex virus type 1 thymidine kinase. The Journal Of General Virology. Vol. 64 ( Pt 12). (December 1): 2679.

Lang JC; Spandidos DA; Wilkie NM. 1984. Transcriptional regulation of a herpes simplex virus immediate early gene is mediated through an enhancer-type sequence. The EMBO Journal. Vol. 3, no. 2. (February 1): 389.

Lang JC; Spandidos DA. 1986. The structure and function of eukaryotic enhancer elements and their role in oncogenesis. Anticancer Research. Vol. 6, no. 3 Pt B. (May 1): 437.

Bailleul B, Lang JC, Wilkie NM and Balmain A. 1988. A human T24 Ha-ras cassette suitable for expression studies in eukaryotic cells. Nucleic Acids Research. Vol. 16: 359.

Lang JC; Talbot S; Wilkie NM. 1988. pUC vectors capable of conferring neomycin resistance to eukaryotic cells. Nucleic Acids Research. Vol. 16, no. 15. (August 11): 7736.

Lang JC; Whitelaw B; Talbot S; Wilkie NM. 1988. Transcriptional regulation of the human c-myc gene. The British Journal Of Cancer. Supplement. Vol. 9. (December 1): 62.

Spandidos DA; Lang JC. 1989. In vitro cell transformation by ras oncogenes. Critical Reviews In Oncogenesis. Vol. 1, no. 2. (January 1): 195.

Spandidos DA; Lang JC. 1989. Immortalization by truncated myc or ras genes and synergism between myc and ras genes in cell transformation. Anticancer Research. Vol. 9, no. 4. (July 1): 1149.

Frame MC; Wilkie NM; Darling AJ; Chudleigh A; Pintzas A; Lang JC; Gillespie DA. 1991. Regulation of AP-1/DNA complex formation in vitro. Oncogene. Vol. 6, no. 2. (February 1): 205.

Khan MZ; Spandidos DA; Kerr DJ; McNicol AM; Lang JC; De Ridder L; Freshney RI. 1991. Oncogene transfection of mink lung cells: effect on growth characteristics in vitro and in vivo. Anticancer Research. Vol. 11, no. 3. (May 1): 1343.

Spandidos DA; Zoumpourlis V; Lang JC. 1991. Cis-platin responsive sequences in the human c-myc promoter. Anticancer Research. Vol. 11, no. 3. (May 1): 1339.

Lang JC; Wilkie NM; Clark AM; Chudleigh A; Talbot S; Whitelaw B; Frame MC. 1991. Regulatory domains within the P0 promoter of human c-myc. Oncogene. Vol. 6, no. 11. (November 1): 2067.

Ballingall KT, Wright H, Redmond J, Dutia BM, Hopkins J, Lang JC, Deverson EV, Howard JC, Puris N, and Haig D. 1992. Expression and characterization of ovine major histocompatibilty complex class II (OLA-DR) genes. Animal Genetics, no. 23: 347-359.

Bryans M, Lucas JM, Wilkie N, Burrow K, Clark AM and Lang JC. 1992. Binding of transcription factor Sp1 to exon 1 of c-myc is altered in Burkitts lymphoma. International Journal of Oncology, no. 1: 175-180.

Coulter LJ, Moss HWM, Lang JC, and McGeoch DJ. 1993. A mutant of herpes simplex virus type 1 in which the the UL13 protein kinase gene is disrupted. Journal of Gen Virol, no. 74: 387-95.

Lucas JM; Wilkie NM; Lang JC. 1993. c-MYC repression of promoter activity through core promoter elements. Biochemical And Biophysical Research Communications. Vol. 194, no. 3. (August 16): 1446.

Lucas JM; Lang JC. 1993. A convenient and efficient method for growing and short-term storage of miniprep bacterial cultures. Biotechniques. Vol. 15, no. 5. (November 1): 823.

Bryans M; Lang JC; Wilkie NM. 1993. Changes in in vivo protein-DNA interactions occur at the c-myc P2 promoter during differentiation. Biochemical And Biophysical Research Communications. Vol. 197, no. 3. (December 30): 1363.

Lucas JM, Bryans M, Lo K, Wilkie NM, and Lang JC. 1994. Expression of cyclin D1 in squamous cell carcinomas of the head and neck. International Journal of Oncology. Vol. 5: 469-72.

Lucas JM; Bryans M; Lo K; Wilkie NM; Freshney M; Thornton D; Lang JC. 1994. The FGF-4 promoter is required for transformation and is active in both embryonal and somatic cells. Oncology Research. Vol. 6, no. 3. (January 1): 139.

Gramza AW; Lucas JM; Mountain RE; Schuller DE; Lang JC. 1995. Efficient method for preparing normal and tumor tissue for RNA extraction. Biotechniques. Vol. 18, no. 2. (February 1): 228.

Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT. 1995. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha. Cancer Gene Therapy. Vol. 2, no. 2. (June 1): 113.

Bryans M; Lucas JM; Knobloch TJ; Wilkie NM; Lang JC. 1995. Regulation of FGF-4 enhancer activity by transcription factor NF-Y. Biochemical And Biophysical Research Communications. Vol. 211, no. 2. (June 15): 519.

Kenny JJ; Knobloch TJ; Augustus M; Carter KC; Rosen CA; Lang JC. 1997. GRS, a novel member of the Bcl-2 gene family, is highly expressed in multiple cancer cell lines and in normal leukocytes. Oncogene. Vol. 14, no. 8. (February 27): 997.

Wu J; Payson RA; Lang JC; Chiu IM. 1997. Activation of fibroblast growth factor 8 gene expression in human embryonal carcinoma cells. The Journal Of Steroid Biochemistry And Molecular Biology. Vol. 62, no. 1. (May 1): 1.

Wang D; Song H; Evans JA; Lang JC; Schuller DE; Weghorst CM. 1997. Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis. Vol. 18, no. 11. (November 1): 2285.

Walker MJ; Silliman E; Dayton MA; Lang JC. 1998. The expression of C-myb in human metastatic melanoma cell lines and specimens. Anticancer Research. Vol. 18, no. 2A. (March 1): 1129.

Lang JC; Tobin EJ; Knobloch TJ; Schuller DE; Bartynski KJ; Mountain RE; Nicholson R; DeYoung BR; Weghorst CM. 1998. Frequent mutation of p16 in squamous cell carcinoma of the head and neck. The Laryngoscope. Vol. 108, no. 6. (June 1): 923.

Danahey DG; Tobin EJ; Schuller DE; Bier-Laning CM; Weghorst CM; Lang JC. 1999. p16 mutation frequency and clinical correlation in head and neck cancer. Acta Oto-Laryngologica. Vol. 119, no. 2. (March 1): 285.

Costello JF; Frühwald MC; Smiraglia DJ; Rush LJ; Robertson GP; Gao X; Wright FA; Feramisco JD; Peltomäki P; Lang JC; Schuller DE; Yu L; Bloomfield CD; Caligiuri MA; Yates A; Nishikawa R; Su Huang H; Petrelli NJ; Zhang X; O'Dorisio MS; Held WA; Cavenee WK; Plass C. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genetics. Vol. 24, no. 2. (February 1): 132.

Lang JC; Schuller DE. 2001. Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck. British Journal Of Cancer. Vol. 84, no. 2. (January 1): 237.

Poi MJ; Yen T; Li J; Song H; Lang JC; Schuller DE; Pearl DK; Casto BC; Tsai MD; Weghorst CM. 2001. Somatic INK4a-ARF locus mutations: a significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck. Molecular Carcinogenesis. Vol. 30, no. 1. (January 1): 26.

Smiraglia DJ; Rush LJ; Frühwald MC; Dai Z; Held WA; Costello JF; Lang JC; Eng C; Li B; Wright FA; Caligiuri MA; Plass C. 2001. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Human Molecular Genetics. Vol. 10, no. 13. (June 15): 1413.

Knobloch TJ; Lynch MA; Song H; DeGroff VL; Casto BC; Adams EM; Alam KY; Lang JC; Schuller DE; Weghorst CM. 2001. Analysis of TGF-beta type I receptor for mutations and polymorphisms in head and neck cancers. Mutation Research. Vol. 479, no. 1-2. (August 8): 131.

Dungan KM; Wei TY; Nace JD; Poulin ML; Chiu IM; Lang JC; Tassava RA. 2002. Expression and biological effect of urodele fibroblast growth factor 1: relationship to limb regeneration. The Journal Of Experimental Zoology. Vol. 292, no. 6. (May 1): 540.

Lang JC; Borchers J; Danahey D; Smith S; Stover DG; Agrawal A; Malone JP; Schuller DE; Weghorst CM; Holinga AJ; Lingam K; Patel CR; Esham B. 2002. Mutational status of overexpressed p16 in head and neck cancer: evidence for germline mutation of p16/p14ARF. International Journal Of Oncology. Vol. 21, no. 2. (August 1): 401.

Smiraglia DJ; Smith LT; Lang JC; Rush LJ; Dai Z; Schuller DE; Plass C. 2003. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). Journal Of Medical Genetics. Vol. 40, no. 1. (January 1): 25.

Sedghizadeh PP; Allen CM; Anderson KE; Kim DH; Kalmar JR; Lang JC. 2004. Oral graft-versus-host disease and programmed cell death: pathogenetic and clinical correlates. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, And Endodontics. Vol. 97, no. 4. (April 1): 491.

Pasche B; Knobloch TJ; Bian Y; Liu J; Phukan S; Rosman D; Kaklamani V; Baddi L; Siddiqui FS; Frankel W; Prior TW; Schuller DE; Agrawal A; Lang J; Dolan ME; Vokes EE; Lane WS; Huang CC; Caldes T; Di Cristofano A; Hampel H; Nilsson I; von Heijne G; Fodde R; Murty VV; de la Chapelle A; Weghorst CM. 2005. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA: The Journal Of The American Medical Association. Vol. 294, no. 13. (October 5): 1634.

Smith LT; Lin M; Brena RM; Lang JC; Schuller DE; Otterson GA; Morrison CD; Smiraglia DJ; Plass C. 2006. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America. Vol. 103, no. 4. (January 24): 982.

Wang D; Grecula JC; Gahbauer RA; Schuller DE; Jatana KR; Biancamano JD; Lang JC. 2006. p16 gene alterations in locally advanced squamous cell carcinoma of the head and neck. Oncology Reports. Vol. 15, no. 3. (March 1): 661.

Lin M; Smith LT; Smiraglia DJ; Kazhiyur-Mannar R; Lang JC; Schuller DE; Kornacker K; Wenger R; Plass C. 2006. DNA copy number gains in head and neck squamous cell carcinoma. Oncogene. Vol. 25, no. 9. (March 2): 1424.

Sedghizadeh PP; Mallery SR; Thompson SJ; Kresty L; Beck FM; Parkinson EK; Biancamano J; Lang JC. 2006. Expression of the serine protease DESC1 correlates directly with normal keratinocyte differentiation and inversely with head and neck squamous cell carcinoma progression. Head & Neck. Vol. 28, no. 5. (May 1): 432.

Bennett KL, Hackanson B, Smith LT, Morrison CD, Lang JC, Schuller DE, Weber F, Eng C, Plass C. 2007. The effects of reactive species on the tumorigenic phenotype of human head and neck squamous cell carcinoma (HNSCC) cells. Anticancer Research. Vol. 6B, no. 27: 3819-3827. (IF: 1.479)

Bennett, Kristi, L; Hackanson, Bjorn; Smith, Laura, T; Morrison, Carl, D; Lang, James, C; Schuller, David, E; Weber, Frank; Eng, Charis; Plass, Christoph. 2007. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer research. Vol. 67, no. 10. (IF: 7.656)

Tong, Xiaodong; Yang, Liying; Lang, James Campbell; Zborowski, Maciej; Chalmers, Jeffrey J. 2007. Application of immunomagnetic cell enrichment in combination with RT-PCR for the detection of rare circulating head and neck tumor cells in human peripheral blood. Cytometry. Part B, Clinical cytometry. Vol. 72, no. 5. (IF: 2.065)

Bennett KL; Hackanson B; Smith LT; Morrison CD; Lang JC; Schuller DE; Weber F; Eng C; Plass C. 2007. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Research. Vol. 67, no. 10. (May 15): 4657.

Tong X; Yang L; Lang JC; Zborowski M; Chalmers JJ. 2007. Application of immunomagnetic cell enrichment in combination with RT-PCR for the detection of rare circulating head and neck tumor cells in human peripheral blood. Cytometry. Part B, Clinical Cytometry. Vol. 72, no. 5. (September 1): 310.

Bradburn JE; Pei P; Kresty LA; Lang JC; Yates AJ; McCormick AP; Mallery SR. 2007. The effects of reactive species on the tumorigenic phenotype of human head and neck squamous cell carcinoma (HNSCC) cells. Anticancer Research. Vol. 27, no. 6B. (November 1): 3819.

Colella S; Richards KL; Bachinski LL; Baggerly KA; Tsavachidis S; Lang JC; Schuller DE; Krahe R. 2008. Molecular signatures of metastasis in head and neck cancer. Head & Neck. Vol. 30, no. 10. (October 1): 1273.

Richards KL; Zhang B; Baggerly KA; Colella S; Lang JC; Schuller DE; Krahe R. 2009. Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. Plos ONE. Vol. 4, no. 3. (January 1): e4941.

Yang L; Lang JC; Balasubramanian P; Jatana KR; Schuller D; Agrawal A; Zborowski M; Chalmers JJ. 2009. Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnology And Bioengineering. Vol. 102, no. 2. (February 1): 521.

Professional Activities

Education

1995 - 1997

High School Student - Daniel Stover. Mentor. The Ohio State University. Columbus, OH.
Key achievements: American Cancer Society Award for Outstanding Research

1995 - 1997

High School Student - Kris Jatana. Advisor. The Ohio State University. Columbus, OH.
Key achievements: State Science Fair Governor's Award for Excellence in Biotechnology Research ($1,000 scholarship) Bowling Green State Governor's Award ($1,000 scholarship) American Junior Academy of Science Presenter, Melville Scholar ($100)

1999	High School Student - Lindsay Barlow. Research Advisor. The Ohio State University. Columbus, OH.

2000	High School Student - Scott Smith. Mentor. The Ohio State University. Columbus, OH.

Undergrad., Grad. and Prof. Courses Taught

The Ohio State University, Pathology 640. 6 credit hours

Summer 1999. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Autumn 1999. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Winter 2000. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Spring 2000. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Summer 2000. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Autumn 2000. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Winter 2001. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Spring 2001. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Summer 2001. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Autumn 2001. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Winter 2002. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Spring 2002. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Summer 2002. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 7 credit hours

Winter 2003. The Ohio State University, INTEGRATED BIOMEDICAL SCIENCE. Individual Studies in Integrated Biomedical Science 793. 2 credit hours

Winter 2003. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Spring 2003. The Ohio State University, MOLECULAR,CELLULAR,AND DEVELOPMENTAL BIOLOGY. Research in Molecular, Cellular, and Developmental Biology 999. 10 credit hours

Winter 2005. The Ohio State University, INTEGRATED BIOMEDICAL SCIENCE. Cancer Biology 702.04. 2 credit hours

Winter 2007. The Ohio State University, INTEGRATED BIOMEDICAL SCIENCE. Cancer Biology 702.04. 0

Winter 2007. The Ohio State University, INTEGRATED BIOMEDICAL SCIENCE. Cancer Biology 702.04. 2 credit hours

2008. The Ohio State University, Molecular Genetics 733. 1 credit hours

Spring 2011. The College of Medicine COLMBUS, Integrated Biomedical Science. Cancer Biology 702.04. 2 credit hours

Spring 2011. The College of Medicine COLMBUS, Integrated Biomedical Science. Biol Humn Dis 3 703.05. 10 credit hours